Skip to main content

Advertisement

Table 3 Effects of subgroups on survival rates in nasopharyngeal carcinoma underwent CV-IMRT versus RV-IMRT

From: Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study

Variate 3-year OS 3-year PFS 3-year DMFS 3-year LRRFS
CV-IMRT RV-IMRT P CV-IMRT RV-IMRT P CV-IMRT RV-IMRT P CV-IMRT RV-IMRT P
Sex Female 91.7% 95.5% 1 91.7% 95.5% 1 100.0% 95.5% 0.478 91.7% 100.0% 0.49
Male 87.9% 91.2% 0.583 81.8% 82.4% 1 89.4% 88.2% 1 90.9% 91.2% 1
Age < 45 95.0% 90.0% 0.675 95.0% 80.0% 0.087 97.5% 85.0% 0.108 97.5% 90.0% 0.359
≥45 84.0% 94.0% 0.2 76.0% 90.0% 0.108 88.0% 94.0% 0.487 86.0% 96.0% 0.16
T stage T1–2 86.5% 94.0% 0.319 82.7% 88.0% 0.579 90.4% 94.0% 0.716 92.3% 94.0% 1
T3–4 92.1% 90.0% 1 86.8% 82.5% 0.756 94.7% 85.0% 0.264 89.5% 92.5% 0.708
N stage N0–1 97.4% 100.0% 1 94.7% 92.1% 1 97.4% 94.7% 1 97.4% 94.7% 1
N2–3 82.7% 86.5% 0.787 76.9% 80.8% 0.811 88.5% 86.5% 1 86.5% 92.3% 0.526
Clinical stage I-II 100.0% 100.0% 95.5% 95.5% 1 95.5% 100.0% 1 100.0% 95.5% 1
III-IV 85.3% 89.7% 0.605 80.9% 82.4% 1 91.2% 86.8% 0.585 88.2% 92.6% 0.561
  1. OS overall survival, PFS progression-free survival, DMFS distant metastasis-free survival, LRRFS locoregional recurrence-free survival, CV-IMRT conventional-volume intensity-modulated radiation therapy, RV-IMRT reduced-volume intensity-modulated radiation therapy